Curriculum
Patrick Flamen, MD, PhD, is the Director of the Nuclear Medicine Department of the Hôpital Universitaire de Bruxelles (H.U.B) which integrates the nuclear medicine services of the Jules Bordet lnstitute - a leading comprehensive cancer center – and the Hôpital Erasme, the general academic hospital of the Université Libre de Bruxelles (ULB).
Under his leadership, the department evolved into a nationally and internationally recognized center of excellence in nuclear medicine and radiotheranostics.
The nuclear medicine department is equipped with cutting-edge infrastructure, including three PET-CT scanners, four SPECT-CT scanners, an IBA cyclotron, a GMP-certified radiopharmacy, a dedicated hospital ward for radionuclide therapies, and a preclinical theranostic research lab (ATHENO).
Dr. Flamen earned his MD from the University of Ghent in 1990, specialized in Nuclear Medicine at the Vrije Universiteit Brussel (VUB), and completed his PhD in Biomedical Sciences at the University of Leuven (KUL) in 2001, focusing on the value of FDG PET imaging in digestive oncology.
His research is centered on the development and clinical translation of innovative nuclear medicine applications in oncology, with a dual emphasis on molecular imaging using PET/CT and radiotheranostic therapies with targeted radiopharmaceuticals.
He has been a pioneer in Belgium and Europe, in introducing several targeted radionuclide treatments, including Lu-177 DOTATATE for neuroendocrine tumors, Lu-177 PSMA for metastatic prostate cancer, radioembolization for liver tumors, radioimmunotherapy of CD20-positive lymphomas, and Radium-223 for bone metastasis palliation.
Dr. Flamen is actively involved in numerous academic and industry-sponsored clinical trials and currently contributes to four European Horizon IHI projects: Accelerate, Thera4Care, Oasis, Compass.
He has authored and co-authored 250 peer-reviewed publications and five book chapters, with more than 9.000 citations and an H-index of 50 on ResearchGate.
Currently he holds an academic appointment as Professor at the Université Libre de Bruxelles (ULB).
He previously served as President of the Therapy Working Group of the Belgian Scientific Association of Nuclear medicine (BELNUC).